Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
John M. Dineen Insider Profile
4 Followers
John M. Dineen, Director at Merrimack Pharmaceuticals, holds 1.83K shares in Cognizant (Ticker: CTSH), holds 455.00 shares in Lam Research (Ticker: LRCX), holds 0.00 shares in Syneos Health (Ticker: SYNH). Most recently, John M. Dineen Bought ― shares of Cognizant on Nov 15, 2023 for an estimated value of 108.74K.
John M. Dineen Merrimack Pharmaceuticals (MACK)Director
Merrimack Pharmaceuticals (MACK)
Director
Ranked #70,616 out of 98,564 Corporate Insiders
Profitable Transactions
0 out of 2 Profitable Transactions
Average Return
-25.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that John M. Dineen holds in companies
Most Profitable Insider Trade
The most profitable trade made by John M. Dineen
John M. Dineen's Trading History
Merrimack Pharmaceuticals
Aug 13, 2015
Director
Informative Buy
1.01M
$1.47M
Cognizant
Nov 15, 2023
Director
Informative Buy
108.74K
$123.82K
Syneos Health
Sep 28, 2023
―
Uninformative Sell
973.05K
$0.00
Lam Research
Nov 13, 2023
Director
Uninformative Buy
―
$403.78K
List of latest transactions for each holding click on a transaction to see John M. Dineen's performance on stock
You May Also Like
John M. Dineen insider profile FAQ
What is the percentage of profitable transactions made by John M. Dineen?
The percentage of profitable transactions made by John M. Dineen is 0%.
What is the average return per transaction made by John M. Dineen?
The average return per transaction made by John M. Dineen is -25.50%.
What stocks does John M. Dineen hold?
John M. Dineen holds: MACK, CTSH, SYNH, LRCX stocks.
What was John M. Dineen’s latest transaction?
John M. Dineen latest transaction was an Informative Buy of $108.74K.
What was John M. Dineen's most profitable transaction?
John M. Dineen’s most profitable transaction was an Informative Buy of CTSH stock on November 15, 2023. The return on the trade was -0.60%.
What is John M. Dineen's role in Merrimack Pharmaceuticals?
John M. Dineen's role in Merrimack Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.